MedTrace Logo

A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

NCT04052932 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 594

Last updated 2022-06-13

No results posted yet for this study

Summary

This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to placebo and Allopurinol in patients with gout

Conditions

Interventions

DRUG

SHR4640 dose1

tablets，dose1，QD

DRUG

SHR4640 dose2

tablets，dose2，QD

DRUG

Placebo oral tablet

tablets，QD

DRUG

Allopurinol 300 MG

tablets，300mg，QD

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chunde Bao · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-16
Primary Completion
2021-07-14
Completion
2021-07-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04052932 on ClinicalTrials.gov